Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy

Kidney International

Volumn 58, Issue 6, 2000, Pages 2390-2399

  Kim, Yoon Goo ^a,b,c,d   Suga, Shin Ichi ^a,b,c,d   Kang, Duk Hee ^a,b,c,d   Jeffferson, J Ashley ^a,b,c,d   Mazzali, Marilda ^a,b,c,d   Gordon, Katherine L ^a,b,c,d   Matsui, Katsuyuki ^a,b,c,d   Breiteneder Geleff, Silvana ^a,b,c,d   Shankland, Stuart J ^a,b,c,d   Hughes, Jeremy ^a,b,c,d   Kerjaschki, Dontscho ^a,b,c,d   Schreiner, George F ^a,b,c,d   Johnson, Richard J ^a,b,c,d  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c UNIVERSITY OF VIENNA   (Austria)

^d SCIOS INC   (United States)

Author keywords

Angiogenesis; Endothelium; Hemolytic uremic syndrome; Ischemia

Indexed keywords

IMMUNOGLOBULIN G; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; HEMOLYTIC UREMIC SYNDROME; INTERSTITIAL NEPHRITIS; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY PERFUSION; MALE; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; RAT; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 0033667542     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2000.00422.x     Document Type: Article

References (34)

1. The hemolytic uremic syndrome
2. Hemolytic uremic syndrome and thrombotic thrombocytopenic purpura
3. Escherichia coli O157:H7 and the hemolytic uremic syndrome
4. The hemolytic uremic syndrome
5. Long-term outcome and prognostic indicators in the hemolytic-uremic syndrome
6. A 20-year population-based study of postdiarrheal hemolytic uremic syndrome in Utah
7. Long-term renal outcome of childhood haemolytic uraemic syndrome
8. Long-term (15-25 years) outcome of childhood hemolytic-uremic syndrome
9. A new model of renal microvascular endothelial injury
10. Role of vascular endothelial growth factor in the regulation of angiogenesis
11. Therapeutic angiogenesis: A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model
12. Vascular endothelial growth factor administration in chronic myocardial ischemia
13. Arterial gene transfer for therapeutic angiogenesis in patients with peripheral artery disease
14. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia
15. Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: Preliminary clinical results
16. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs
17. Mechanisms of clearance of immune complexes from peritubular capillaries in the rat
18. CD59 protects glomerular endothelial cells from immune-mediated thrombotic microangiopathy in rats
19. The biology of vascular endothelial growth factor
20. Antibodies defining rat endothelial cells: RECA-1, a pan-endothelial cell-specific monoclonal antibody
21. Participation of glomerular endothelial cells in the capillary repair of glomerulonephritis
22. A beta 1-integrin receptor for fibronectin in human kidney glomeruli
23. Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis
24. Salt-sensitive hypertension develops after short-term exposure to angiotensin II
25. Tubulointerstitial disease in aging. Evidence for underlying peritubular capillary damage, a potential role for renal ischemia
26. VEGF is required for growth and survival of neonatal mice
27. The C5b-9 membrane attack complex mediates endothelial cell apoptosis in experimental glomerulonephritis
28. Physiology of renal hypoxia
29. Hypoxia of the renal medulla: Its implications for disease
30. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity
31. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody
32. Progressive renal disease: The chronic hypoxia hypothesis
33. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells
34. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis